**6. Conclusions**

As incidence of HBV and HCV associated HCC continues to decrease with effective antiviral treatment, NAFLD associated HCC is becoming the leading cause of HCC. In light of the rising prevalence of NAFLD associated HCC, its unique pathogenesis and findings suggestive inferior response to immune checkpoint inhibitors, future clinical trials should assess whether HCC etiology influence the efficacy of a given treatment.
